The experts agreed that perioperative approaches in muscle-invasive bladder cancer continue to evolve. Ongoing data will ...
A subcutaneously injected version of Merck cancer immunotherapy Keytruda is now FDA approved, a regulatory decision that gives patients a less burdensome dosing option and provides the pharmaceutical ...
Muscle-invasive bladder cancer management is challenging for cisplatin-ineligible patients due to limited treatment options and high recurrence rates. The Padcev-Keytruda combination therapy ...
Merck has obtained the Food and Drug Administration’s permission for Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback